Add
HTGC to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| HTGC > SEC Filings for HTGC > Form 10-K on 28-Feb-2013 | All Recent SEC Filings |
28-Feb-2013
Annual Report
The matters discussed in this report, as well as in future oral and written statements by management of Hercules Technology Growth Capital, that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:
• our future operating results;
• our business prospects and the prospects of our prospective portfolio companies;
• the impact of investments that we expect to make;
• the impact of a protracted decline in the liquidity of credit markets on our business;
• our informal relationships with third parties including in the venture capital industry;
• the expected market for venture capital investments and our addressable market;
• the dependence of our future success on the general economy and its impact on the industries in which we invest;
• our ability to access debt markets and equity markets;
• the ability of our portfolio companies to achieve their objectives;
• our expected financings and investments;
• our regulatory structure and tax status;
• our ability to operate as a BDC, a SBIC and a RIC;
• the adequacy of our cash resources and working capital;
• the timing of cash flows, if any, from the operations of our portfolio companies;
• the timing, form and amount of any dividend distributions;
• the impact of fluctuations in interest rates on our business;
• the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and
• our ability to recover unrealized losses.
For a discussion of factors that could cause our actual results to differ from forward-looking statements contained in this report, please see the discussion under "Item 1A. Risk Factors." You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.
The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under "Item 1A-Risk Factors" and "Forward-Looking Statements" of this Item 7.
Overview
We are a specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and clean-technology industries at all stages of development. We source our investments through our principal office located in Silicon Valley, as well as through its additional offices in Boston, MA, Boulder, CO and McLean, VA.
Our goal is to be the leading structured debt financing provider of choice for venture capital-backed companies in technology-related markets requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related markets including technology, biotechnology, life science, and clean-technology industries and to offer a full suite of growth capital products up and down the capital structure. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We use the term "structured debt with warrants" to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or rights to purchase common or preferred stock. Our structured debt with warrants investments will typically be secured by some or all of the assets of the portfolio company.
Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our equity-related investments. Our primary business objectives are to increase our net income, net operating income and net asset value by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related markets with attractive current yields and the potential for equity appreciation and realized gains. Our structured debt investments typically include warrants or other equity interests, giving us the potential to realize equity-like returns on a portion of our investments. Our equity ownership in our portfolio companies may represent a controlling interest. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related markets is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.
We are an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company under the 1940 Act. As a business development company, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in "qualifying assets," including securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less.
From incorporation through December 31, 2005, we were taxed as a corporation under Subchapter C of the Internal Revenue Code, or the Code. As of January 1, 2006, we have elected to be treated for federal income tax purposes as a regulated investment company, or a RIC, under Subchapter M of the Code. Pursuant to this election, we generally will not have to pay corporate-level taxes on any income that we distribute to our stockholders. However, such an election and qualification to be treated as a RIC requires that we comply with certain requirements contained in Subchapter M of the Code. For example, a RIC must meet certain requirements, including source-of income, asset diversification and income distribution requirements. The income source requirement mandates that we receive 90% or more of our income from qualified earnings, typically referred to as "good income."
Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology-related companies at various stages of their development. Consistent with regulatory requirements, we invest primarily in United States based companies and to a lesser extent in foreign companies.
We regularly engage in discussions with third parties in respect of various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We or our subsidiaries may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.
Portfolio and Investment Activity
The total fair value of our investment portfolio was $906.3 million at December 31, 2012 as compared to $652.9 million at December 31, 2011.
The fair value of the loan portfolio at December 31, 2012 was approximately $827.5 million, compared to a fair value of approximately $585.8 million at December 31, 2011. The fair value of the equity portfolio at December 31, 2012 and 2011 was approximately $49.2 million and $37.1 million, respectively. The fair value of our warrant portfolio at December 31, 2012 and 2011 was approximately $29.5 million and $30.0 million, respectively.
Portfolio Activity
Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments are dependent upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt investments represent our future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and do not represent our future cash requirements.
Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding terms sheets are subject to completion of our due diligence and final approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent our future cash requirements.
Our portfolio activity for the years ended December 31, 2012 and 2011 was comprised of the following:
Year Ended
December 31,
(in millions) 2012 2011
Debt Commitments(1)
New portfolio company $ 362.3 $ 402.5
Existing portfolio company 274.3 225.8
Total $ 636.6 $ 628.3
Funded Debt Investments
New portfolio company $ 267.9 $ 338.7
Existing portfolio company 191.4 94.7
Total $ 459.3 $ 433.4
Funded Equity Investments
New portfolio company $ 6.0 $ -
Existing portfolio company 3.7 2.1
Total $ 9.7 $ 2.1
As of
December 31,
2012 2011
Unfunded Contractual Commitments(2)
Total $ 61.9 $ 168.2
Non-Binding Term Sheets
New portfolio company $ 70.0 $ 82.5
Existing portfolio company - -
Total $ 70.0 $ 82.5
|
(1) Includes restructured loans.
(2) Includes unfunded contractual commitments in 21 new and existing portfolio companies. Approximately $35.6 million of these unfunded origination activity commitments as of December 31, 2012 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available.
We receive payments in our loan portfolio based on scheduled amortization of the outstanding balances. In addition, we receive repayments of some of our loans prior to their scheduled maturity date. The frequency or volume of these repayments may fluctuate significantly from period to period. During the year ended December 31, 2012, we received normal principal amortization repayments of approximately $120.7 million, and early repayments and working line of credit pay-downs of approximately $125.1 million. During the year ended December 31, 2012, we restructured certain debt investments for approximately $85.0 million and converted approximately $669,000 of debt to equity.
Total portfolio investment activity (inclusive of unearned income) as of and for each of the years ended December 31, 2012 and 2011 was as follows:
December 31, December 31,
(in millions) 2012 2011
Beginning Portfolio $ 652.9 $ 472.0
New Fundings 469.9 433.8
Warrants not related to current period fundings (0.2 ) 1.5
Principal payments received on investments (120.7 ) 16.1
Early payoffs (125.1 ) (65.2 )
Restructure payoffs (48.5 ) (182.1 )
Restructure fundings 85.0 (16.1 )
Accretion of loan discounts and paid-in-kind principal 21.3 17.0
New loan fees (12.8 ) (10.4 )
Conversion of "Other Assets" 9.6 0.2
Debt Converted to Equity 0.6 -
Proceeds from sale of investments (7.2 ) (20.6 )
Net realized (loss) gain on investments (14.1 ) 2.1
Net change in unrealized appreciation (depreciation) (4.4 ) 4.6
Ending Portfolio $ 906.3 $ 652.9
|
The following table shows the fair value of our portfolio of investments by asset class as of December 31, 2012 and December 31, 2011 (excluding unearned income).
December 31, 2012 December 31, 2011
Investments at Fair Percentage of Total Investments at Fair Percentage of Total
(in thousands) Value Portfolio Value Portfolio
Senior secured debt
with warrants $ 652,041 72.0 % $ 482,268 73.9 %
Senior secured debt 205,049 22.6 % 133,544 20.4 %
Preferred stock 33,885 3.7 % 30,181 4.6 %
Common Stock 15,325 1.7 % 6,877 1.1 %
$ 906,300 100.0 % $ 652,870 100.0 %
|
A summary of our investment portfolio at value by geographic location is as follows:
December 31, 2012 December 31, 2011
Investments at Fair Percentage of Total Investments at Fair Percentage of Total
(in thousands) Value Portfolio Value Portfolio
United States $ 901,041 99.4 % $ 634,736 97.2 %
England 5,259 0.6 % 8,266 1.3 %
Iceland - - 4,970 0.7 %
Ireland - - 3,842 0.6 %
Canada - - 672 0.1 %
Israel - - 384 0.1 %
$ 906,300 100.0 % $ 652,870 100.0 %
|
As of December 31, 2012, we held warrants or equity positions in two companies which have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. There can be no assurance that these companies will complete their initial public offering in a timely manner or at all.
Changes in Portfolio
We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $1.0 million to $25.0 million. Our debt investments have a term of between
two and seven years and typically bear interest at a rate ranging from Prime to approximately 14.0% as of December 31, 2012. In addition to the cash yields received on our loans, in some instances, our loans may also include any of the following: end-of-term payments, exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt. Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan's yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. We had approximately $2.0 million and $4.5 million of unamortized fees at December 31, 2012 and December 31, 2011, respectively, and approximately $6.8 million and $4.4 million in exit fees receivable at December 31, 2012 and December 31, 2011, respectively.
We have loans in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is added to the principal balance of the loan and recorded as interest income. To maintain our status as a RIC, this non-cash source of income must be paid out to stockholders in the form of dividends even though we have not yet collected the cash. Amounts necessary to pay these dividends may come from available cash or the liquidation of certain investments. We recorded approximately $1.5 million and $1.7 million in PIK income in the twelve month periods ended December 31, 2012 and 2011.
In some cases, we may collateralize our investments by obtaining a first priority security interest in a portfolio company's assets, which may include their intellectual property. In other cases, we may obtain a negative pledge covering a company's intellectual property.
At December 31, 2012, approximately 62.4% of our portfolio company loans were secured by a first priority security in all of the assets of the portfolio company, 36.0% of the loans were to portfolio companies that were prohibited from pledging or encumbering their intellectual property and 1.6% of portfolio company loans had an equipment only lien.
Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the security for emerging-growth, expansion-stage and established-stage companies. In addition, certain loans may include an interest-only period ranging from three to eighteen months for emerging-growth and expansion-stage companies and longer for established-stage companies. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.
The effective yield on our debt investments during the year was 14.37% and was attributed in part to interest charges and fees related to loan restructurings and acceleration of fee income recognition from early loan repayments. The overall weighted average yield to maturity of our loan investments was approximately 12.91% at December 31, 2012, a slight increase compared to 12.64% at December 31, 2011. The weighted average yield to maturity is computed using the interest rates in effect at the inception of each of the loans, and includes amortization of the loan facility fees, commitment fees and market premiums or discounts over the expected life of the debt investments, weighted by their respective costs when averaged and based on the assumption that all contractual loan commitments have been fully funded and held to maturity.
Portfolio Composition
Our portfolio companies are primarily privately held companies which are active in the drug discovery and development, internet consumer and business services, clean technology, software, drug delivery, medical device and equipment, media/content/info, communications and networking, information services, healthcare services, diagnostic, specialty pharmaceuticals, biotechnology tools, surgical devices, consumer and business products, semiconductors, electronics and computer hardware and therapeutic industry sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value is often vested in intangible assets and intellectual property.
As of December 31, 2012, approximately 65.8% of the fair value of our portfolio was composed of investments in five industries: 20.8% was composed of investments in the drug discovery and development industry, 15.0% was composed of investments in the internet consumer and business services industry, 14.0% was composed of investments in the clean technology industry, 8.2% was composed of investments in the drug delivery industry and 7.8% was composed of investments in the software industry.
The following table shows the fair value of our portfolio by industry sector at December 31, 2012 and December 31, 2011:
December 31, 2012 December 31, 2011
Investments at Fair Percentage of Total Investments at Fair Percentage of Total
(in thousands) Value Portfolio Value Portfolio
Drug Discovery &
Development $ 188,479 20.8 % $ 131,428 20.1 %
Internet Consumer &
Business Services 136,149 15.0 % 117,542 18.0 %
Clean Technology 126,600 14.0 % 64,587 9.9 %
Drug Delivery 74,218 8.2 % 62,665 9.6 %
Software 70,838 7.8 % 27,850 4.3 %
Medical Device & Equipment 54,575 6.0 % - 0.0 %
Information Services 53,523 5.9 % 45,850 7.0 %
Media/Content/Info 51,534 5.7 % 38,476 5.9 %
Communications & Networking 37,560 4.1 % 28,618 4.4 %
. . .
|
|
|